Ophthalmic drugs are preparations used for the treatment of eye diseases and disorders such as cataract, glaucoma, color blindness, diabetic macular edema, CMV retinitis, and age-related macular degeneration. The ophthalmic drugs market is witnessing significant growth, due to increase in prevalence of eye disorders and rise in use of combination therapies for treatment of ophthalmic disorders, especially glaucoma. Combination therapies have various advantages over traditional medication such improvement in patient compliance and efficacy. Moreover, surge in prevalence of ophthalmic disorders, rise in geriatric population globally, and change in demographics fuel the ophthalmic drugs market growth. The global ophthalmic drugs market was valued at $29,613 million in 2016, and is expected to reach $42,663 million by 2023, registering a CAGR of 5.3% from 2017 to 2023.
The ophthalmic drugs market is segmented based on indication, type, distribution channel, dosage form, technology, therapeutic class, and geography. Depending on indication, the market is divided into dry eye, glaucoma, infection/inflammation/allergy, retinal disorders, and others. On the basis of type, the market is bifurcated into prescription drugs and over-the-counter drugs. By distribution channel, it is categorized into hospital pharmacies, online pharmacies, drug stores, and others. According to dosage form, it is classified into liquid ophthalmic drug forms, semisolid ophthalmic drug forms, solid ophthalmic drug forms, multicompartment drug delivery systems, and other ophthalmic drug forms. As per technology, the market is segmented into biologics, cell therapy, gene therapy, drug delivery, small molecule, and others. Based on therapeutic class, it is classified into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, and anti-allergy drugs. Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
As per ophthalmic drugs market analysis, in the recent years, Asia-Pacific reported significant growth in the ophthalmic drugs market, owing to steady increase in the prevalence of glaucoma in the Asian population. In addition, increase in the number of people suffering from primary angle-closure glaucoma in Japan, China, and South Korea supplement this growth further.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Indication
By Type
By Dosage Form
By Technology
By Distribution Channel
By Therapeutic Class
By Geography
KEY MARKET PLAYERS
The other players in the value chain include (profiles not included in the report)
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. MARKET SHARE ANALYSIS, 2016
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.1.1. Increase in focus of key players to develop combination therapies for the treatment of ophthalmic disorders
3.5.1.2. Rise in prevalence of ophthalmic disorders worldwide
3.5.1.3. Change in the demographics across the globe
3.5.2. Restraints
3.5.2.1. Longer timelines required for the development of ophthalmic drugs
3.5.2.2. Risk of side effects associated with ophthalmic drugs
3.5.3. Opportunity
3.5.3.1. Increase in investment by market players in the emerging economies
CHAPTER 4 OPHTHALMIC DRUGS MARKET, BY INDICATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. DRY EYE
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. GLAUCOMA
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. INFECTION/INFLAMMATION/ALLERGY
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. RETINAL DISORDERS
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Wet age-related macular degeneration
4.5.4.1. Market size and forecast
4.5.5. Dry age-related macular degeneration
4.5.5.1. Market size and forecast
4.5.6. Diabetic retinopathy
4.5.6.1. Market size and forecast
4.5.7. Others
4.5.7.1. Market size and forecast
4.6. OTHERS
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
CHAPTER 5 OPHTHALMIC DRUGS MARKET, BY TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. PRESCRIPTION DRUGS
5.2.1. Market size and forecast
5.3. OVER-THE-COUNTER DRUGS
5.3.1. Market size and forecast
CHAPTER 6 OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITAL PHARMACIES
6.2.1. Market size and forecast
6.3. DRUG STORES
6.3.1. Market size and forecast
6.4. ONLINE PHARMACIES
6.4.1. Market size and forecast
6.5. OTHERS
6.5.1. Market size and forecast
CHAPTER 7 OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. LIQUID OPHTHALMIC DRUG FORMS
7.2.1. Market size and forecast
7.3. SEMISOLID OPHTHALMIC DRUG FORMS
7.3.1. Market size and forecast
7.4. SOLID OPHTHALMIC DRUG FORMS
7.4.1. Market size and forecast
7.5. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS
7.5.1. Market size and forecast
7.6. OTHER OPHTHALMIC DRUG FORMS
7.6.1. Market size and forecast
CHAPTER 8 OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. ANTI-INFLAMMATORY
8.2.1. Market size and forecast
8.2.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
8.2.3. Steroids
8.3. ANTI-INFECTIVE
8.3.1. Market size and forecast
8.3.2. Antifungal drugs
8.3.3. Antibacterial drugs
8.3.4. Others
8.4. ANTI-GLAUCOMA
8.4.1. Market size and forecast
8.4.2. Beta blockers
8.4.3. Prostaglandin analogs
8.4.4. Others
8.5. ANTI-ALLERGY
8.5.1. Market size and forecast
CHAPTER 9 OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY
9.1. OVERVIEW
9.1.1. Market size and forecast
9.2. BIOLOGICS
9.2.1. Market size and forecast
9.3. CELL THERAPY
9.3.1. Market size and forecast
9.4. GENE THERAPY
9.4.1. Market size and forecast
9.5. SMALL MOLECULE
9.5.1. Market size and forecast
9.6. DRUG DELIVERY
9.6.1. Market size and forecast
9.7. OTHERS
9.7.1. Market size and forecast
CHAPTER 10 OPHTHALMIC DRUGS MARKET, BY REGION
10.1. OVERVIEW
10.1.1. Market size and forecast
10.2. NORTH AMERICA
10.2.1. Key market trends
10.2.2. Key growth factors and opportunities
10.2.3. Market size and forecast, by country
10.2.4. Market size and forecast, by indication
10.2.5. Market size and forecast, by type
10.2.6. Market size and forecast, by technology
10.2.7. Market size and forecast, by distribution channel
10.2.8. Market size and forecast, by dosage form
10.2.9. Market size and forecast, by therapeutic class
10.2.9.1. U.S., by indication
10.2.9.2. U.S., by type
10.2.9.3. U.S., by distribution channel
10.2.9.4. U.S., by dosage form
10.2.9.5. U.S., by technology
10.2.9.6. U.S., by therapeutic class
10.2.9.7. Canada, by indication
10.2.9.8. Canada, by type
10.2.9.9. Canada, by distribution channel
10.2.9.10. Canada, by dosage form
10.2.9.11. Canada, by technology
10.2.9.12. Canada, by therapeutic class
10.2.9.13. Mexico, by indication
10.2.9.14. Mexico, by type
10.2.9.15. Mexico, by distribution channel
10.2.9.16. Mexico, by dosage form
10.2.9.17. Mexico, by technology
10.2.9.18. Mexico, by therapeutic class
10.3. EUROPE
10.3.1. Key market trends
10.3.2. Key growth factors and opportunities
10.3.3. Europe Market size and forecast, by country
10.3.4. Market size and forecast, by indication
10.3.5. Market size and forecast, by type
10.3.6. Market size and forecast, by technology
10.3.7. Market size and forecast, by distribution channel
10.3.8. Market size and forecast, by dosage form
10.3.9. Market size and forecast, by therapeutic class
10.3.9.1. Germany, by indication
10.3.9.2. Germany, by type
10.3.9.3. Germany, by distribution channel
10.3.9.4. Germany, by dosage form
10.3.9.5. Germany, by technology
10.3.9.6. Germany, by therapeutic class
10.3.9.7. France, by indication
10.3.9.8. France, by type
10.3.9.9. France, by distribution channel
10.3.9.10. France, by dosage form
10.3.9.11. France, by technology
10.3.9.12. France, by therapeutic class
10.3.9.13. UK, by indication
10.3.9.14. UK, by type
10.3.9.15. UK, by distribution channel
10.3.9.16. UK, by dosage form
10.3.9.17. UK, by technology
10.3.9.18. UK, by therapeutic class
10.3.9.19. Italy, by indication
10.3.9.20. Italy, by type
10.3.9.21. Italy, by distribution channel
10.3.9.22. Italy, by dosage form
10.3.9.23. Italy, by technology
10.3.9.24. Italy, by therapeutic class
10.3.9.25. Spain, by indication
10.3.9.26. Spain, by type
10.3.9.27. Spain, by distribution channel
10.3.9.28. Spain, by dosage form
10.3.9.29. Spain, by technology
10.3.9.30. Spain, by therapeutic class
10.3.9.31. Rest of Europe, by indication
10.3.9.32. Rest of Europe, by type
10.3.9.33. Rest of Europe, by distribution channel
10.3.9.34. Rest of Europe, by dosage form
10.3.9.35. Rest of Europe, by technology
10.3.9.36. Rest of Europe, by therapeutic class
10.4. ASIA-PACIFIC
10.4.1. Key market trends
10.4.2. Key growth factors and opportunities
10.4.3. Asia-Pacific Market size and forecast, by country
10.4.4. Market size and forecast, by indication
10.4.5. Market size and forecast, by type
10.4.6. Market size and forecast, by technology
10.4.7. Market size and forecast, by distribution channel
10.4.8. Market size and forecast, by dosage form
10.4.9. Market size and forecast, by therapeutic class
10.4.9.1. Japan, by indication
10.4.9.2. Japan, by type
10.4.9.3. Japan, by distribution channel
10.4.9.4. Japan, by dosage form
10.4.9.5. Japan, by technology
10.4.9.6. Japan, by therapeutic class
10.4.9.7. China, by indication
10.4.9.8. China, by type
10.4.9.9. China, by distribution channel
10.4.9.10. China, by dosage form
10.4.9.11. China, by technology
10.4.9.12. China, by therapeutic class
10.4.9.13. India, by indication
10.4.9.14. India, by type
10.4.9.15. India, by distribution channel
10.4.9.16. India, by dosage form
10.4.9.17. India, by technology
10.4.9.18. India, by therapeutic class
10.4.9.19. Australia, by indication
10.4.9.20. Australia, by type
10.4.9.21. Australia, by distribution channel
10.4.9.22. Australia, by dosage form
10.4.9.23. Australia, by technology
10.4.9.24. Australia, by therapeutic class
10.4.9.25. South Korea, by indication
10.4.9.26. South Korea, by type
10.4.9.27. South Korea, by distribution channel
10.4.9.28. South Korea, by dosage form
10.4.9.29. South Korea, by technology
10.4.9.30. South Korea, by therapeutic class
10.4.9.31. Rest of Asia-Pacific, by indication
10.4.9.32. Rest of Asia-Pacific, by type
10.4.9.33. Rest of Asia-Pacific, by distribution channel
10.4.9.34. Rest of Asia-Pacific, by dosage form
10.4.9.35. Rest of Asia-Pacific, by technology
10.4.9.36. Rest of Asia-Pacific, by therapeutic class
10.5. LAMEA
10.5.1. Key market trends
10.5.2. Key growth factors and opportunities
10.5.3. LAMEA Market size and forecast, by country
10.5.4. Market size and forecast, by indication
10.5.5. Market size and forecast, by type
10.5.6. Market size and forecast, by technology
10.5.7. Market size and forecast, by distribution channel
10.5.8. Market size and forecast, by dosage form
10.5.9. Market size and forecast, by therapeutic class
10.5.9.1. Brazil, by indication
10.5.9.2. Brazil, by type
10.5.9.3. Brazil, by distribution channel
10.5.9.4. Brazil, by dosage form
10.5.9.5. Brazil, by technology
10.5.9.6. Brazil, by therapeutic class
10.5.9.7. South Africa, by indication
10.5.9.8. South Africa, by type
10.5.9.9. South Africa, by distribution channel
10.5.9.10. South Africa, by dosage form
10.5.9.11. South Africa, by technology
10.5.9.12. South Africa, by therapeutic class
10.5.9.13. Turkey, by indication
10.5.9.14. Turkey, by type
10.5.9.15. Turkey, by distribution channel
10.5.9.16. Turkey, by dosage form
10.5.9.17. Turkey, by technology
10.5.9.18. Turkey, by therapeutic class
10.5.9.19. Saudi Arabia, by indication
10.5.9.20. Saudi Arabia, by type
10.5.9.21. Saudi Arabia, by distribution channel
10.5.9.22. Saudi Arabia, by dosage form
10.5.9.23. Saudi Arabia, by technology
10.5.9.24. Saudi Arabia, by therapeutic class
10.5.9.25. Rest of LAMEA, by indication
10.5.9.26. Rest of LAMEA, by type
10.5.9.27. Rest of LAMEA, by distribution channel
10.5.9.28. Rest of LAMEA, by dosage form
10.5.9.29. Rest of LAMEA, by technology
10.5.9.30. Rest of LAMEA, by therapeutic class
CHAPTER 11 COMPANY PROFILES
11.1. ALLERGAN PLC
11.1.1. Company overview
11.1.2. Company snapshot
11.1.3. Operating business segments
11.1.4. Product portfolio
11.1.5. Business performance
11.1.6. Key strategic moves and developments
11.2. F. HOFFMANN-LA ROCHE AG (GENENTECH, INC.)
11.2.1. Company overview
11.2.2. Company snapshot
11.2.3. Operating business segments
11.2.4. Product portfolio
11.2.5. Business performance
11.2.6. Key strategic moves and developments
11.3. NOVARTIS AG (ALCON-A DIVISION OF NOVARTIS)
11.3.1. Company overview
11.3.2. Company snapshot
11.3.3. Operating business segments
11.3.4. Product portfolio
11.3.5. Business performance
11.3.6. Key strategic moves and developments
11.4. PFIZER INC.
11.4.1. Company overview
11.4.2. Company snapshot
11.4.3. Operating business segments
11.4.4. Product portfolio
11.4.5. Business performance
11.4.6. Key strategic moves and developments
11.5. REGENERON PHARMACEUTICALS INC.
11.5.1. Company overview
11.5.2. Company snapshot
11.5.3. Operating business segments
11.5.4. Product portfolio
11.5.5. Business performance
11.5.6. Key strategic moves and developments
11.6. SANTEN PHARMACEUTICAL CO., LTD.
11.6.1. Company overview
11.6.2. Company snapshot
11.6.3. Operating business segments
11.6.4. Product portfolio
11.6.5. Business performance
11.6.6. Key strategic moves and developments
11.7. SHIRE PLC
11.7.1. Company overview
11.7.2. Company snapshot
11.7.3. Operating business segments
11.7.4. Product portfolio
11.7.5. Business performance
11.7.6. Key strategic moves and developments
11.8. SUN PHARMACEUTICAL INDUSTRIES LIMITED
11.8.1. Company overview
11.8.2. Company snapshot
11.8.3. Operating business segments
11.8.4. Product portfolio
11.8.5. Business performance
11.8.6. Key strategic moves and developments
11.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.( ACTAVIS GENERICS)
11.9.1. Company overview
11.9.2. Company snapshot
11.9.3. Operating business segments
11.9.4. Product portfolio
11.9.5. Business performance
11.9.6. Key strategic moves and developments
11.10. VALEANT PHARMACEUTICAL INTERNATIONAL, INC. (BAUSCH & LOMB INC.)
11.10.1. Company overview
11.10.2. Company snapshot
11.10.3. Operating business segments
11.10.4. Product portfolio
11.10.5. Business performance
11.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 1. NOVARTIS OPHTHALMOLOGIC PIPELINE PORTFOLIO, JULY 2011
TABLE 2. GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 3. OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY REGION, 2016-2023 ($MILLION)
TABLE 4. OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY REGION, 2016-2023 ($MILLION)
TABLE 5. OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY REGION, 2016-2023 ($MILLION)
TABLE 6. OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 7. OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY TYPE, 2016-2023 ($MILLION)
TABLE 8. OPHTHALMIC DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016-2023 ($MILLION)
TABLE 9. OPHTHALMIC DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016-2023 ($MILLION)
TABLE 10. OPHTHALMIC DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2016-2023 ($MILLION)
TABLE 11. OPHTHALMIC DRUGS MARKET FOR OTHER, BY REGION, 2016-2023 ($MILLION)
TABLE 12. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 14. PRESCRIPTION OPHTHALMIC DRUGS OFFERED BY BAUSCH + LOMB
TABLE 15. PRESCRIPTION OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 16. OPHTHALMIC DRUGS AVAILABLE OVER THE COUNTER FOR THE TREATMENT OF DRY EYE
TABLE 17. OVER-THE-COUNTER OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 19. OPHTHALMIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2016-2023 ($MILLION)
TABLE 20. OPHTHALMIC DRUGS MARKET FOR DRUG STORES, BY REGION, 2016-2023 ($MILLION)
TABLE 21. OPHTHALMIC DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2016-2023 ($MILLION)
TABLE 22. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 24. OPHTHALMIC DRUGS ADMINISTERED IN LIQUID FORMS
TABLE 25. LIQUID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. OPHTHALMIC DRUGS ADMINISTERED IN SEMISOLID FORMS
TABLE 27. SEMISOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 28. VARIOUS TYPES OF SOLID OPHTHALMIC DRUG FORMS
TABLE 29. SOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 30. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 31. OTHER OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 33. OPHTHALMIC DRUGS MARKET FOR ANTI-INFLAMMATORY, BY REGION, 2016-2023 ($MILLION)
TABLE 34. OPHTHALMIC DRUGS MARKET FOR ANTI-INFECTIVE, BY REGION, 2016-2023 ($MILLION)
TABLE 35. OPHTHALMIC DRUGS MARKET FOR ANTI-GLAUCOMA, BY REGION, 2016-2023 ($MILLION)
TABLE 36. OPHTHALMIC DRUGS MARKET FOR ANTI-ALLERGY, BY REGION, 2016-2023 ($MILLION)
TABLE 37. GLOBAL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 38. FDA-APPROVED OCULAR BIOLOGICS
TABLE 39. OPHTHALMIC DRUGS MARKET FOR BIOLOGICS, BY REGION, 2016-2023 ($MILLION)
TABLE 40. OPHTHALMIC DRUGS MARKET FOR CELL THERAPY, BY REGION, 2016-2023 ($MILLION)
TABLE 41. OPHTHALMIC DRUGS MARKET FOR GENE THERAPY, BY REGION, 2016-2023 ($MILLION)
TABLE 42. OPHTHALMIC DRUGS MARKET FOR SMALL MOLECULE, BY REGION, 2016-2023 ($MILLION)
TABLE 43. OPHTHALMIC DRUGS MARKET FOR DRUG DELIVERY, BY REGION, 2016-2023 ($MILLION)
TABLE 44. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 45. OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 46. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 47. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 48. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 49. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 50. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 51. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 52. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 53. U.S. OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 54. U.S. OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 55. U.S. OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 56. U.S. OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 57. U.S. OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 58. U.S. OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 59. CANADA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 60. CANADA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 61. CANADA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 62. CANADA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 63. CANADA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 64. CANADA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 65. MEXICO OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 66. MEXICO OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 67. MEXICO OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 68. MEXICO OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 69. MEXICO OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 70. MEXICO OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 71. EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 72. EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 73. EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 74. EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 75. EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 76. EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 77. EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 78. GERMANY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 79. GERMANY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 80. GERMANY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 81. GERMANY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 82. GERMANY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 83. GERMANY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 84. FRANCE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 85. FRANCE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 86. FRANCE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 87. FRANCE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 88. FRANCE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 89. FRANCE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 90. UK OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 91. UK OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 92. UK OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 93. UK OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 94. UK OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 95. UK OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 96. ITALY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 97. ITALY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 98. ITALY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 99. ITALY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 100. ITALY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 101. ITALY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 102. SPAIN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 103. SPAIN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 104. SPAIN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 105. SPAIN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 106. SPAIN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 107. SPAIN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 108. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 109. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 110. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 111. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 112. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 113. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 114. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 115. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 116. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 117. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 118. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 119. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 120. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 121. JAPAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 122. JAPAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 123. JAPAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 124. JAPAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 125. JAPAN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 126. JAPAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 127. CHINA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 128. CHINA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 129. CHINA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 130. CHINA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 131. CHINA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 132. CHINA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 133. INDIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 134. INDIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 135. INDIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 136. INDIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 137. INDIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 138. INDIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 139. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 140. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 141. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 142. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 143. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 144. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 145. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 146. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 147. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 148. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 149. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 150. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 151. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 152. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 153. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 154. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 155. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 156. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 157. LAMEA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 158. LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 159. LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 160. LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 161. LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 162. LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 163. LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 164. BRAZIL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 165. BRAZIL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 166. BRAZIL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 167. BRAZIL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 168. BRAZIL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 169. BRAZIL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 170. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 171. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 172. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 173. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 174. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 175. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 176. TURKEY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 177. TURKEY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 178. TURKEY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 179. TURKEY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 180. TURKEY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 181. TURKEY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 182. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 183. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 184. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 185. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 186. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 187. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 188. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 189. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 190. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 191. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
TABLE 192. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 193. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
TABLE 194. ALLERGAN: COMPANY SNAPSHOT
TABLE 195. ALLERGEN: OPERATING SEGMENTS
TABLE 196. ALLERGAN: PRODUCT PORTFOLIO
TABLE 197. ROCHE: COMPANY SNAPSHOT
TABLE 198. ROCHE: OPERATING SEGMENT
TABLE 199. ROCHE: PRODUCT PORTFOLIO
TABLE 200. NOVARTIS: COMPANY SNAPSHOT
TABLE 201. NOVARTIS: OPERATING SEGMENTS
TABLE 202. NOVARTIS: PRODUCT PORTFOLIO
TABLE 203. PFIZER: COMPANY SNAPSHOT
TABLE 204. PFIZER: OPERATING SEGMENTS
TABLE 205. PFIZER: PRODUCT PORTFOLIO
TABLE 206. REGENERON: COMPANY SNAPSHOT
TABLE 207. REGENERON: PRODUCT PORTFOLIO
TABLE 208. SANTEN PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 209. SANTEN PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 210. SANTEN PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 211. SHIRE: COMPANY SNAPSHOT
TABLE 212. SHIRE: PRODUCT PORTFOLIO
TABLE 213. SUN PHARMA: COMPANY SNAPSHOT
TABLE 214. SUN PHARMA: OPERATING SEGMENTS
TABLE 215. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 216. TEVA: COMPANY SNAPSHOT
TABLE 217. TEVA: OPERATING SEGMENTS
TABLE 218. TEVA: PRODUCT PORTFOLIO
TABLE 219. VALEANT: COMPANY SNAPSHOT
TABLE 220. VALEANT: OPERATING SEGMENTS
TABLE 221. VALEANT: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. GLOBAL OPHTHALMIC DRUGS MARKET SNAPSHOT, 2016-2023
FIGURE 2. OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023
FIGURE 3. MARKET SEGMENTATION
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 6. TOTAL NUMBER OF STRATEGIES
FIGURE 7. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 8. HIGH BARGAINING POWER OF BUYERS
FIGURE 9. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10. HIGH THREAT OF NEW ENTRANTS
FIGURE 11. HIGH THREAT OF SUBSTITUTION
FIGURE 12. MODERATE COMPETITIVE RIVALRY
FIGURE 13. MARKET SHARE ANALYSIS, 2016
FIGURE 14. DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 15. PREVALENT CASES OF AMD IN THE U.S., 2010
FIGURE 16. GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016
FIGURE 17. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 18. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 19. ROCHE: NET-SALES, 2014-2016 ($MILLION)
FIGURE 20. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 22. NOVARTIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. NOVARTIS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. ALCON: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. ALCON: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 29. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 30. REGENERON: NET SALES, 2014-2016 ($MILLION)
FIGURE 31. SANTEN PHARMACEUTICAL: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. SANTEN PHARMACEUTICAL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. SANTEN PHARMACEUTICAL: REVENUE SHARE BY PRODUCT CATEGORY, 2017 (%)
FIGURE 34. SANTEN PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2017(%)
FIGURE 35. SHIRE: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. SHIRE: REVENUE SHARE BY PRODUCT CATEGORY, 2016 (%)
FIGURE 37. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38. SUN PHARMA: NET SALES, 2015-2017 ($MILLION)
FIGURE 39. SUN PHARMA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 40. SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 41. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 42. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 43. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 44. VALEANT: NET SALES, 2014-2016 ($MILLION)
FIGURE 45. VALEANT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 46. VALEANT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
